Strong Revenue and EBITDA Growth
Third quarter revenue increased 8.8% to $1.58 billion. Adjusted EBITDA grew 46% in the third quarter to $143 million, with margins expanding 240 basis points to 9.1%.
Growth in Surgical Volumes
Surgical volumes improved with total surgeries up 1.4% in the third quarter, reversing a small decline of 0.4% in the first half of the year. Inpatient surgery growth was 9.7%.
Improved Cash Flow and Leverage
Cash flow from operating activities was strong at $154 million compared to $90 million for the third quarter of 2024. Lease-adjusted net leverage improved from 2.7x to 2.5x.
IMPACT Program for Cost Optimization
The IMPACT program is expected to generate an annual benefit of more than $40 million through contract renegotiations and targeted staffing adjustments.
Sustained Demand in Key Markets
Markets are growing 2x to 3x faster than the national average, driven by demographic tailwinds and rising care complexity.